Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1831 to 1845 of 7615 results

  1. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

    Awaiting development [GID-TA11076] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690

    Awaiting development [GID-TA11073] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764

    Awaiting development [GID-TA11049] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763

    Awaiting development [GID-TA11048] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]

    Awaiting development [GID-TA11011] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]

    Awaiting development [GID-TA10967] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]

    Awaiting development [GID-TA10960] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development [GID-TA11404] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years TS ID 11959

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Third molars (impacted) - prophylactic removal [ID898]

    In development [GID-TAG525] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Nipocalimab for treating generalised myasthenia gravis TS ID 11958

    Awaiting development [GID-TA11492] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941

    Awaiting development [GID-TA11481] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    Awaiting development [GID-TA10747] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Bipolar disorder: assessment and management (extraordinary review)

    In development [GID-NG10380] Expected publication date: TBC

    NICE guideline
    In development